Thrombolysis in patients with pulmonary embolism and elevated heart-type fatty acid-binding protein levels
Recent studies have reported that a novel cardiac biomarker, heart-type fatty acid-binding protein (h-FABP), significantly predicts mortality inpatients with pulmonary embolism (PE) at intermediate risk. The aim of this study was to evaluate the effect of thrombolytic therapy on prognosis of the int...
Gespeichert in:
| Veröffentlicht in: | Journal of thrombosis and thrombolysis 2014-05, Vol.37 (4), p.483-489 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 489 |
|---|---|
| container_issue | 4 |
| container_start_page | 483 |
| container_title | Journal of thrombosis and thrombolysis |
| container_volume | 37 |
| creator | Gul, Enes Elvin Can, Ilknur Kayrak, Mehmet Abdulhalikov, Turyan Erdogan, Halil Ibrahim Altunbas, Gokhan Ozdemir, Kurtulus Gok, Hasan |
| description | Recent studies have reported that a novel cardiac biomarker, heart-type fatty acid-binding protein (h-FABP), significantly predicts mortality inpatients with pulmonary embolism (PE) at intermediate risk. The aim of this study was to evaluate the effect of thrombolytic therapy on prognosis of the intermediate risk acute PE patients with elevated levels of h-FABP. This is non-interventional, prospective, and single-center cohort study where 80 patients (mean age 62 ± 17 years, 32 men) with confirmed acute PE were included. Only patients with PE at intermediate risk (echocardiographic signs of right ventricular overload but without evidence for hypotension or shock) were included in the study. h-FABP and other biomarkers were measured upon admission to the emergency department. Thrombolytic (Thrl) therapy was administered at the physician’s discretion. Of the included 80 patients, 24 were h-FABP positive (30 %). 14 patients (58 %) with positive h-FABP had clinical deterioration during the hospital course and required inotropic support and 12 of these patients died. However, of 56 patients with negative test, only 7 patients worsened or needed inotropic support and five patients died during the hospital stay. Mortality of patients with PE at intermediate risk was 21 %. The 30-day mortality rate was significantly higher in h-FABP(+) patients compared to h-FABP(−) patients (9 vs. 50 %,
p
|
| doi_str_mv | 10.1007/s11239-013-1008-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1516398920</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3273539241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-9c48a71335143e10a2a60c7632c59d1f5693368b6b5a197eec77045c46daab083</originalsourceid><addsrcrecordid>eNp1kU9r3DAQxUVpaDZpP0AuQdBLLmr0X9YxhKQpBHJJoTcjy7NZLbbsSHLLfvto2TSEQk_DML95M7yH0Bmj3xil5jIzxoUllAlS-4aYD2jFlBHESP7rI1pRyy1RgqpjdJLzllJqLeWf0DGXXEur7AptHzdpGrtp2OWQcYh4diVALBn_CWWD52UYp-jSDsMeCnnELvYYBvjtCvR4Ay4VUnYz4LUrZYedDz3pQuxDfMJzmgpUzUrDkD-jo7UbMnx5rafo5-3N4_UduX_4_uP66p54SVUh1svGGSaEYlIAo447Tb3Rgntle7ZW2gqhm053yjFrALwxVCovde9cRxtxii4OuvX88wK5tGPIHobBRZiW3DLFtLCN5bSiX_9Bt9OSYv1uTympqke6UuxA-TTlnGDdzimM1ZSW0XYfRHsIoq1B7PumNXXn_FV56Ubo3zb-Ol8BfgByHcUnSO9O_1f1BcdTk6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1515459596</pqid></control><display><type>article</type><title>Thrombolysis in patients with pulmonary embolism and elevated heart-type fatty acid-binding protein levels</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Gul, Enes Elvin ; Can, Ilknur ; Kayrak, Mehmet ; Abdulhalikov, Turyan ; Erdogan, Halil Ibrahim ; Altunbas, Gokhan ; Ozdemir, Kurtulus ; Gok, Hasan</creator><creatorcontrib>Gul, Enes Elvin ; Can, Ilknur ; Kayrak, Mehmet ; Abdulhalikov, Turyan ; Erdogan, Halil Ibrahim ; Altunbas, Gokhan ; Ozdemir, Kurtulus ; Gok, Hasan</creatorcontrib><description>Recent studies have reported that a novel cardiac biomarker, heart-type fatty acid-binding protein (h-FABP), significantly predicts mortality inpatients with pulmonary embolism (PE) at intermediate risk. The aim of this study was to evaluate the effect of thrombolytic therapy on prognosis of the intermediate risk acute PE patients with elevated levels of h-FABP. This is non-interventional, prospective, and single-center cohort study where 80 patients (mean age 62 ± 17 years, 32 men) with confirmed acute PE were included. Only patients with PE at intermediate risk (echocardiographic signs of right ventricular overload but without evidence for hypotension or shock) were included in the study. h-FABP and other biomarkers were measured upon admission to the emergency department. Thrombolytic (Thrl) therapy was administered at the physician’s discretion. Of the included 80 patients, 24 were h-FABP positive (30 %). 14 patients (58 %) with positive h-FABP had clinical deterioration during the hospital course and required inotropic support and 12 of these patients died. However, of 56 patients with negative test, only 7 patients worsened or needed inotropic support and five patients died during the hospital stay. Mortality of patients with PE at intermediate risk was 21 %. The 30-day mortality rate was significantly higher in h-FABP(+) patients compared to h-FABP(−) patients (9 vs. 50 %,
p
< 0.001). Multivariate analysis revealed h-FABP as the only 30 day mortality predictor (HR 7.81, CI 1.59–38.34,
p
= 0.01). However, thrl therapy did dot affect the survival of these high-risk patients. Despite, h-FABP was successful to predict 30-days mortality in patients with PE at intermediate risk; it is suggested to be failed in determining the patients who will benefit from thrl therapy.</description><identifier>ISSN: 0929-5305</identifier><identifier>EISSN: 1573-742X</identifier><identifier>DOI: 10.1007/s11239-013-1008-7</identifier><identifier>PMID: 24264959</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Aged ; Cardiology ; Disease-Free Survival ; Fatty Acid Binding Protein 3 ; Fatty Acid-Binding Proteins - blood ; Female ; Follow-Up Studies ; Hematology ; Humans ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Pulmonary Embolism - blood ; Pulmonary Embolism - drug therapy ; Pulmonary Embolism - mortality ; Risk Factors ; Survival Rate ; Thrombolytic Therapy</subject><ispartof>Journal of thrombosis and thrombolysis, 2014-05, Vol.37 (4), p.483-489</ispartof><rights>Springer Science+Business Media New York 2013</rights><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-9c48a71335143e10a2a60c7632c59d1f5693368b6b5a197eec77045c46daab083</citedby><cites>FETCH-LOGICAL-c405t-9c48a71335143e10a2a60c7632c59d1f5693368b6b5a197eec77045c46daab083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11239-013-1008-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11239-013-1008-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24264959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gul, Enes Elvin</creatorcontrib><creatorcontrib>Can, Ilknur</creatorcontrib><creatorcontrib>Kayrak, Mehmet</creatorcontrib><creatorcontrib>Abdulhalikov, Turyan</creatorcontrib><creatorcontrib>Erdogan, Halil Ibrahim</creatorcontrib><creatorcontrib>Altunbas, Gokhan</creatorcontrib><creatorcontrib>Ozdemir, Kurtulus</creatorcontrib><creatorcontrib>Gok, Hasan</creatorcontrib><title>Thrombolysis in patients with pulmonary embolism and elevated heart-type fatty acid-binding protein levels</title><title>Journal of thrombosis and thrombolysis</title><addtitle>J Thromb Thrombolysis</addtitle><addtitle>J Thromb Thrombolysis</addtitle><description>Recent studies have reported that a novel cardiac biomarker, heart-type fatty acid-binding protein (h-FABP), significantly predicts mortality inpatients with pulmonary embolism (PE) at intermediate risk. The aim of this study was to evaluate the effect of thrombolytic therapy on prognosis of the intermediate risk acute PE patients with elevated levels of h-FABP. This is non-interventional, prospective, and single-center cohort study where 80 patients (mean age 62 ± 17 years, 32 men) with confirmed acute PE were included. Only patients with PE at intermediate risk (echocardiographic signs of right ventricular overload but without evidence for hypotension or shock) were included in the study. h-FABP and other biomarkers were measured upon admission to the emergency department. Thrombolytic (Thrl) therapy was administered at the physician’s discretion. Of the included 80 patients, 24 were h-FABP positive (30 %). 14 patients (58 %) with positive h-FABP had clinical deterioration during the hospital course and required inotropic support and 12 of these patients died. However, of 56 patients with negative test, only 7 patients worsened or needed inotropic support and five patients died during the hospital stay. Mortality of patients with PE at intermediate risk was 21 %. The 30-day mortality rate was significantly higher in h-FABP(+) patients compared to h-FABP(−) patients (9 vs. 50 %,
p
< 0.001). Multivariate analysis revealed h-FABP as the only 30 day mortality predictor (HR 7.81, CI 1.59–38.34,
p
= 0.01). However, thrl therapy did dot affect the survival of these high-risk patients. Despite, h-FABP was successful to predict 30-days mortality in patients with PE at intermediate risk; it is suggested to be failed in determining the patients who will benefit from thrl therapy.</description><subject>Aged</subject><subject>Cardiology</subject><subject>Disease-Free Survival</subject><subject>Fatty Acid Binding Protein 3</subject><subject>Fatty Acid-Binding Proteins - blood</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Pulmonary Embolism - blood</subject><subject>Pulmonary Embolism - drug therapy</subject><subject>Pulmonary Embolism - mortality</subject><subject>Risk Factors</subject><subject>Survival Rate</subject><subject>Thrombolytic Therapy</subject><issn>0929-5305</issn><issn>1573-742X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU9r3DAQxUVpaDZpP0AuQdBLLmr0X9YxhKQpBHJJoTcjy7NZLbbsSHLLfvto2TSEQk_DML95M7yH0Bmj3xil5jIzxoUllAlS-4aYD2jFlBHESP7rI1pRyy1RgqpjdJLzllJqLeWf0DGXXEur7AptHzdpGrtp2OWQcYh4diVALBn_CWWD52UYp-jSDsMeCnnELvYYBvjtCvR4Ay4VUnYz4LUrZYedDz3pQuxDfMJzmgpUzUrDkD-jo7UbMnx5rafo5-3N4_UduX_4_uP66p54SVUh1svGGSaEYlIAo447Tb3Rgntle7ZW2gqhm053yjFrALwxVCovde9cRxtxii4OuvX88wK5tGPIHobBRZiW3DLFtLCN5bSiX_9Bt9OSYv1uTympqke6UuxA-TTlnGDdzimM1ZSW0XYfRHsIoq1B7PumNXXn_FV56Ubo3zb-Ol8BfgByHcUnSO9O_1f1BcdTk6g</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Gul, Enes Elvin</creator><creator>Can, Ilknur</creator><creator>Kayrak, Mehmet</creator><creator>Abdulhalikov, Turyan</creator><creator>Erdogan, Halil Ibrahim</creator><creator>Altunbas, Gokhan</creator><creator>Ozdemir, Kurtulus</creator><creator>Gok, Hasan</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20140501</creationdate><title>Thrombolysis in patients with pulmonary embolism and elevated heart-type fatty acid-binding protein levels</title><author>Gul, Enes Elvin ; Can, Ilknur ; Kayrak, Mehmet ; Abdulhalikov, Turyan ; Erdogan, Halil Ibrahim ; Altunbas, Gokhan ; Ozdemir, Kurtulus ; Gok, Hasan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-9c48a71335143e10a2a60c7632c59d1f5693368b6b5a197eec77045c46daab083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Cardiology</topic><topic>Disease-Free Survival</topic><topic>Fatty Acid Binding Protein 3</topic><topic>Fatty Acid-Binding Proteins - blood</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Pulmonary Embolism - blood</topic><topic>Pulmonary Embolism - drug therapy</topic><topic>Pulmonary Embolism - mortality</topic><topic>Risk Factors</topic><topic>Survival Rate</topic><topic>Thrombolytic Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gul, Enes Elvin</creatorcontrib><creatorcontrib>Can, Ilknur</creatorcontrib><creatorcontrib>Kayrak, Mehmet</creatorcontrib><creatorcontrib>Abdulhalikov, Turyan</creatorcontrib><creatorcontrib>Erdogan, Halil Ibrahim</creatorcontrib><creatorcontrib>Altunbas, Gokhan</creatorcontrib><creatorcontrib>Ozdemir, Kurtulus</creatorcontrib><creatorcontrib>Gok, Hasan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and thrombolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gul, Enes Elvin</au><au>Can, Ilknur</au><au>Kayrak, Mehmet</au><au>Abdulhalikov, Turyan</au><au>Erdogan, Halil Ibrahim</au><au>Altunbas, Gokhan</au><au>Ozdemir, Kurtulus</au><au>Gok, Hasan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thrombolysis in patients with pulmonary embolism and elevated heart-type fatty acid-binding protein levels</atitle><jtitle>Journal of thrombosis and thrombolysis</jtitle><stitle>J Thromb Thrombolysis</stitle><addtitle>J Thromb Thrombolysis</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>37</volume><issue>4</issue><spage>483</spage><epage>489</epage><pages>483-489</pages><issn>0929-5305</issn><eissn>1573-742X</eissn><abstract>Recent studies have reported that a novel cardiac biomarker, heart-type fatty acid-binding protein (h-FABP), significantly predicts mortality inpatients with pulmonary embolism (PE) at intermediate risk. The aim of this study was to evaluate the effect of thrombolytic therapy on prognosis of the intermediate risk acute PE patients with elevated levels of h-FABP. This is non-interventional, prospective, and single-center cohort study where 80 patients (mean age 62 ± 17 years, 32 men) with confirmed acute PE were included. Only patients with PE at intermediate risk (echocardiographic signs of right ventricular overload but without evidence for hypotension or shock) were included in the study. h-FABP and other biomarkers were measured upon admission to the emergency department. Thrombolytic (Thrl) therapy was administered at the physician’s discretion. Of the included 80 patients, 24 were h-FABP positive (30 %). 14 patients (58 %) with positive h-FABP had clinical deterioration during the hospital course and required inotropic support and 12 of these patients died. However, of 56 patients with negative test, only 7 patients worsened or needed inotropic support and five patients died during the hospital stay. Mortality of patients with PE at intermediate risk was 21 %. The 30-day mortality rate was significantly higher in h-FABP(+) patients compared to h-FABP(−) patients (9 vs. 50 %,
p
< 0.001). Multivariate analysis revealed h-FABP as the only 30 day mortality predictor (HR 7.81, CI 1.59–38.34,
p
= 0.01). However, thrl therapy did dot affect the survival of these high-risk patients. Despite, h-FABP was successful to predict 30-days mortality in patients with PE at intermediate risk; it is suggested to be failed in determining the patients who will benefit from thrl therapy.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24264959</pmid><doi>10.1007/s11239-013-1008-7</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0929-5305 |
| ispartof | Journal of thrombosis and thrombolysis, 2014-05, Vol.37 (4), p.483-489 |
| issn | 0929-5305 1573-742X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1516398920 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Cardiology Disease-Free Survival Fatty Acid Binding Protein 3 Fatty Acid-Binding Proteins - blood Female Follow-Up Studies Hematology Humans Male Medicine Medicine & Public Health Middle Aged Pulmonary Embolism - blood Pulmonary Embolism - drug therapy Pulmonary Embolism - mortality Risk Factors Survival Rate Thrombolytic Therapy |
| title | Thrombolysis in patients with pulmonary embolism and elevated heart-type fatty acid-binding protein levels |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T00%3A42%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thrombolysis%20in%20patients%20with%20pulmonary%20embolism%20and%20elevated%20heart-type%20fatty%20acid-binding%20protein%20levels&rft.jtitle=Journal%20of%20thrombosis%20and%20thrombolysis&rft.au=Gul,%20Enes%20Elvin&rft.date=2014-05-01&rft.volume=37&rft.issue=4&rft.spage=483&rft.epage=489&rft.pages=483-489&rft.issn=0929-5305&rft.eissn=1573-742X&rft_id=info:doi/10.1007/s11239-013-1008-7&rft_dat=%3Cproquest_cross%3E3273539241%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1515459596&rft_id=info:pmid/24264959&rfr_iscdi=true |